文献速递放疗物理与技术姑息放疗与转移瘤

临床研究是否服务于全球癌症负担的需求?对当代全球放射治疗随机对照试验的分析

Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-02-11

这项回顾性队列研究分析了2014至2017年发表的694项3期抗癌治疗随机对照试验,其中放疗试验64项(9%),全身治疗试验601项(87%)。放疗试验中47%集中于放疗联合全身药物(25%)和剂量分割改变(22%),头颈癌、肺癌和乳腺癌最常见,宫颈癌仅占3%。放疗试验33%达到主要终点,62%评估根治性 setting,77%在高收入国家开展,17%获产业资助。

要点

  • 2014至2017年发表的3期随机对照试验中,放疗试验仅占9%(64/694),全身治疗试验占87%(601/694)。
  • 放疗随机对照试验中47%集中于放疗联合全身药物(25%)和剂量分割改变(22%)两个方向。
  • 放疗随机对照试验中77%在高收入国家开展,13%在低中收入国家,11%同时涉及两类国家。

核心结论

  • 本研究强调需要加大对放疗随机对照试验的投入,并关注全球开展随机对照试验的不均衡。
  • 研究强调迫切需要在低中收入国家加强癌症临床试验的能力建设,并建立更可持续的资助来源。

研究设计与样本

  • 这是一项回顾性队列研究,纳入2014至2017年发表的所有评估抗癌治疗的3期随机对照试验。
  • 研究队列共694项随机对照试验,其中放疗随机对照试验64项(9%),全身治疗随机对照试验601项(87%)。
  • 随机对照试验按抗癌治疗方式和来源国分类,采用描述性统计比较放疗随机对照试验的研究设计特征、评估的肿瘤类型、干预类型、治疗意图和主要资助来源。

主要发现

  • 放疗随机对照试验中47%集中于两个评估领域:放疗联合全身药物(25%)和剂量分割改变(22%)。
  • 放疗随机对照试验研究最多的癌症为头颈癌(22%)、肺癌(22%)和乳腺癌(14%),宫颈癌试验仅占队列的3%。
  • 放疗随机对照试验中33%达到主要终点,62%评估根治性 setting 的干预,而全身治疗随机对照试验中该比例为31%。
  • 放疗随机对照试验中77%在高收入国家开展,13%在低中收入国家,11%同时在高收入和低中收入国家开展。
  • 放疗随机对照试验中17%获得产业资助,而全身治疗随机对照试验中该比例为79%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Randomized controlled trials (RCTs) are the cornerstone of delivering sustained improvements in cancer outcome. To inform radiation therapy research policy and prioritization, we analyze the radiation therapy RCT landscape including comparison with trials of systemic therapies over the same period, with a specific focus on funding and disparities across income settings. METHODS AND MATERIALS: This retrospective cohort study identified all phase 3 RCTs evaluating anticancer therapies published from 2014 to 2017. RCTs were classified according to anticancer modality and country of origin. Descriptive statistics were used to compare key characteristics of radiation therapy RCT studies according to study design characteristics, tumor types evaluated, types of intervention appraised, treatment intent and main funding sources. RESULTS: The study cohort included 694 RCTs of which 64 were radiation therapy RCTs (9%) compared with 601 systemic therapy RCTs (87%). Among all radiation therapy RCTs, 47% of them focused on 2 areas of evaluation: (1) combining radiation therapy with systemic agents (25%) and (2) changes in dose fractionation (22%). The most common cancers studied were head and neck (22%), lung (22%), and breast (14%), with cervical cancer trials representing only 3% of the cohort. Among the radiation therapy RCTs, 33% of them met their primary endpoint, and 62% assessed interventions in the curative setting compared with 31% in systemic therapy RCTs. For their country locations, 77% of radiation therapy RCTs took place in high-income countries, 13% in low-and-middle-income countries, and 11% in both high-income and low-and-middle-income countries. For funding, 17% of radiation therapy RCTs received funding from industry compared with 79% of systemic therapy RCTs. CONCLUSIONS: This study highlights the need for greater investment in radiation therapy RCTs and the need to look at the disparities in conducting RCTs globally. The study emphases the urgent need for more capacity building for cancer clinical trials in low-and-middle-income countries and more sustainable funding sources.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dodkins J, Hopman WM, Wells JC, et al. Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials. Int J Radiat Oncol Biol Phys. 2022. PMID: 35151802. doi:10.1016/j.ijrobp.2022.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。